Francesco Luzza - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Francesco Luzza

Showing results (151-160 of 159) with videos related to

Pageof 16

Sort By:

You have reached the last page of results.This site can display upto 159 results.

Inflammatory Bowel Diseases|May 17, 2022

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational StudyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 25, 2022

Diagnostic delay in adult coeliac disease: An Italian multicentre studyMarco Vincenzo Lenti, Nicola Aronico, Paola Ilaria Bianchi, et al.

Expert Opinion on Biological Therapy|December 14, 2021

Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.

Intestinal Research|September 29, 2025

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Francesco Costa, et al.

Expert Opinion on Biological Therapy|January 22, 2024

Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.

Advances in Therapy|May 9, 2026

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort StudyAntonio Tursi, Andrea Pasta, Walter Elisei, et al.

Journal of Clinical Medicine|November 13, 2025

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.

Expert Opinion on Biological Therapy|February 27, 2023

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter studyGiammarco Mocci, Antonio Tursi, Giovanni Maconi, et al.

Journal of Clinical Medicine|December 17, 2024

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.

Pageof 16

Search research articles

Showing results (151-160 of 159) with videos related to

Sort By:

Pageof 16

You have reached the last page of results.This site can display upto 159 results.

Inflammatory Bowel Diseases|May 17, 2022

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 25, 2022

Diagnostic delay in adult coeliac disease: An Italian multicentre studyMarco Vincenzo Lenti, Nicola Aronico, Paola Ilaria Bianchi, et al.

Expert Opinion on Biological Therapy|December 14, 2021

Intestinal Research|September 29, 2025

Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Francesco Costa, et al.

Expert Opinion on Biological Therapy|January 22, 2024

Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.

Advances in Therapy|May 9, 2026

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort StudyAntonio Tursi, Andrea Pasta, Walter Elisei, et al.

Journal of Clinical Medicine|November 13, 2025

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.

Expert Opinion on Biological Therapy|February 27, 2023

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter studyGiammarco Mocci, Antonio Tursi, Giovanni Maconi, et al.

Journal of Clinical Medicine|December 17, 2024

Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.

Pageof 16